Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Multiple Myeloma 7Lymphoma, B-Cell 5Pancreatic Neoplasms 4Lymphoma, Non-Hodgkin 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Lymphocytic, Chronic, B-Cell 4Carcinoma, Hepatocellular 4Stomach Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Glioma 3Burkitt Lymphoma 3Recurrence 2Neoplasms 2Melanoma 2Lymphoma 2Lung Neoplasms 2Leukemia, Prolymphocytic, B-Cell 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid 2Esophageal Neoplasms 2Colorectal Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumor 1Simpson-Golabi-Behmel syndrome 1Sarcoma, Synovial 1Prostatic Neoplasms 1Plasmacytoma 1Pelvic Neoplasms 1

Interventions

fludarabine 1Immunotherapy, Adoptive 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Simpson-Golabi-Behmel syndrome × Immunotherapy, Adoptive × Clear all
NCT02723942 2020-07-16

CAR-T Cell Immunotherapy for HCC Targeting GPC3

Fuda Cancer Hospital, Guangzhou

Phase 1/2 Withdrawn
Gastrointestinal

Simpson-Golabi-Behmel syndrome, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡